GH Research (GHRS) Q3 2026 earnings review
GH Research simplifies its depression inhaler, but Phase 3 slips
GH Research, a clinical-stage developer of inhaled depression treatments, cleared key device and regulatory hurdles while pushing its main trial start into next year. Final Phase 1 data showed its new inhaler delivers a consistent single dose, and the Food and Drug Administration gave positive initial feedback on the late-stage trial design. Quarterly net loss narrowed to $12.5 million as research spending paused between trials, leaving $351 million in cash and bonds.
| Cash and marketable securities | $350.6M -$12.1M from last quarter |
|---|---|
| Net loss | $12.5M $14.0M a year ago |
| TRD Phase 3 trial start | Delayed after Q1 2027 vs 2026 plan |
| PPD Phase 3 trial start | H2 2027 new target after 10/10 remission |
⚖️ Verdict: 🟢 Bullish
The story got better because the company resolved its biggest commercial hurdle by replacing a three-dose titration process with a single fixed inhalation that fits into a one-hour clinic visit. Adding former Johnson & Johnson executive Dr. Vanina Popova to run the trials and planning a second pivotal program in postpartum depression also strengthen the pipeline. One caution: the lead depression trial missed its 2026 start target and now awaits a first-quarter 2027 FDA meeting.
The question now is whether a single fixed dose can match the efficacy of the multi-dose regimen used in Phase 2b over a longer four-week window. If one inhalation drives the same deep remission in patients as it did in eight healthy volunteers, the simpler clinic visit wins; if patient responses vary, ditching dose titration could weaken the trial outcome. Final trial design details after the first-quarter FDA meeting will show how many dose arms are required.
🐂 Bull Case
New Inhaler Cuts Treatment to One Dose
GH Research is developing GH001, an inhaled mebufotenin therapy for patients with severe depression. In earlier trials using a third-party vaporizer, doctors gave patients up to three escalating doses in a single visit until the patient reached an intense psychoactive state called a peak experience. The company tested its own proprietary inhaler, the Aerosol Delivery System (ADS), in a Phase 1 trial to simplify this step.
- Device accuracy: delivered 82% to 89% of the loaded drug in lab tests, up from 55% to 79% on the old vaporizer
- Single-dose response: 88% of participants (7 of 8) reached a peak experience on the single dose chosen for late-stage trials
- Old multi-dose response: 23% reached a peak experience on one dose and 86% after up to three doses in Phase 2b
The tighter delivery range matters because clinics struggle to manage multi-hour, multi-step dosing sessions. Because one inhalation now achieves the target response rate, the Irish biotech firm expects the new device "allows for a ~1-hour fixed treatment visit in clinical practice". A predictable one-hour slot makes the therapy far easier for psychiatric clinics to schedule and adopt.
What to watch: the exact milligram dose selected for the Phase 3 trial after the first-quarter FDA meeting. Full trial protocols will show whether regulators accepted the single-dose bridge without requiring additional dosing arms.
FDA Feedback Clears Path for Depression Trial
After years of US regulatory delays, the drug developer received positive initial feedback from the Food and Drug Administration on its late-stage trial design for treatment-resistant depression (TRD), a condition where standard antidepressants fail. The planned trials will compare parallel fixed-dose groups against a placebo over a 12-week double-blind period. Doctors will measure the primary outcome at Week 4 using the Montgomery-Åsberg Depression Rating Scale (MADRS), a standard clinical questionnaire.
To run the studies, the group hired Dr. Vanina Popova as Chief Development Officer "to lead the clinical development of GH001 into our pivotal programs". Popova previously worked at Johnson & Johnson on Spravato, an approved nasal spray for depression, and served as lead author on its Phase 3 trial publication. Agreeing on a four-week primary endpoint and hiring a veteran who ran the main competing trial reduces execution risk.
What to watch: the outcome of the End-of-Phase 2 meeting with the FDA in the first quarter of 2027. Final alignment on the protocol will let the team open clinical sites and begin dosing patients.
Postpartum Depression Trial Reaches Full Remission
GH Research also tested GH001 in an open-label Phase 2a study of ten women with postpartum depression (PPD), severe depression following childbirth. "Women with postpartum depression need treatments that work quickly and ask little of them at a time when they are caring for a newborn," said investigator Dr. Kristina M. Deligiannidis. Every patient in the ten-person study reached full remission within two hours of a single dosing day.
All ten patients remained in remission on Day 8, posting an average MADRS score drop of 35.4 points. Because the response was rapid and complete, management plans to take PPD directly into a late-stage pivotal program using the new single-dose inhaler. This adds a second late-stage indication alongside the main depression program.
What to watch: regulatory feedback on the postpartum depression trial design ahead of its planned start in the second half of 2027. Agency sign-off will confirm whether the small ten-patient study is sufficient to enter Phase 3.
🐻 Bear Case
Lead Depression Trial Slips Into Next Year
For four consecutive quarters, the Dublin-based company told investors it targeted starting its global Phase 3 pivotal program for treatment-resistant depression in 2026. In today's update, the company pushed that start date into next year. It now expects "to hold an End-of-Phase 2 meeting with the FDA in Q1 2027 to finalize the design and to initiate the pivotal program in TRD shortly thereafter".
That timeline shift explain why quarterly research and development spending fell 5% from a year ago to $10.1 million, and dropped 19% from the second quarter by our math. Instead of ramping up spending to open Phase 3 hospital sites late this year, clinical activity slowed after Phase 1 device trials wrapped up. Every quarter of delay pushes out potential drug approval and commercial revenue.
What to watch: the date of the first patient dosed in the Phase 3 depression program in 2027. A gap of more than a few months after the first-quarter FDA meeting would indicate further protocol or site-startup friction.
Single-Dose Device Needs Proof in Patients
The company's standout Phase 2b depression data — a 15.5-point improvement over placebo at Day 8 — used an individualized dosing regimen (IDR). Under that method, doctors gave patients up to three doses in one visit so that 86% reached a peak psychoactive experience. For Phase 3, management is dropping titration and moving to one fixed dose from its new inhaler, citing an 88% peak experience rate.
However, that 88% rate came from just 7 of 8 healthy volunteers in a Phase 1 bridging study, whereas the Phase 2b trial tested 81 severely depressed patients. Furthermore, the Phase 3 primary endpoint will be measured at Week 4 instead of Day 8. If chronically ill patients respond more variably to a single fixed dose than healthy volunteers, four-week efficacy could fall short of Phase 2b results.
What to watch: how many fixed-dose arms the FDA requires in the final Phase 3 trial design in the first quarter of 2027. Testing multiple dose levels would show the agency wants proof of the optimal fixed dose in actual patients.
👓 Other Themes
European Regulators Are Absent From the Plan
Although GH Research is based in Ireland and ran its Phase 2b depression trial in Europe, today's regulatory update focuses entirely on the US Food and Drug Administration. Management outlined FDA feedback and meeting timelines for both depression programs, but did not mention the European Medicines Agency or whether the single-dose inhaler design satisfies European authorities for a global trial.
💲 Other KPIs
Cash and investment-grade bonds fell by $12.1 million from the second quarter's $362.7 million balance by our math, as operating outlays exceeded $3.0 million of interest income. Despite the quarterly burn, the reserve remains up 24.9% from $280.7 million at the end of 2025 following April's $111.2 million share offering.
Research spending fell 4.7% from $10.6 million a year ago and dropped 18.8% from $12.4 million in the second quarter by our math. The company said the decline was "primarily due to decreased technical development and clinical development expenses" after completing its Phase 1 device and healthy-volunteer studies.
Overhead costs decreased 11.9% from $6.0 million a year ago and fell 25.1% from $7.1 million last quarter by our math. Lower professional fees drove the savings, reversing three consecutive quarters of rising administrative spending and helping narrow the quarterly net loss by 11.2% to $12.5 million.
🔮 Guidance
Delayed. The biotech group now plans to start its late-stage treatment-resistant depression trial shortly after an FDA meeting in the first quarter of 2027, pushing the start out of 2026. The company had held the 2026 target since the third quarter of 2025 while it completed Phase 1 bridging studies for its new inhaler.
New. Management set an initial target to begin a pivotal program in postpartum depression in the second half of 2027, subject to regulatory alignment. The trial will use the same single-dose proprietary inhaler planned for the main depression study, following a Phase 2a trial where all ten patients reached remission.
❓ Key Questions
How much will the two Phase 3 programs cost?
Quarterly cash burn dropped to $12.1 million by our math because Phase 1 trials ended before Phase 3 began. Investors need to know how high quarterly research spending will climb once both late-stage depression programs are enrolling patients in 2027.
Why is the primary endpoint at Week 4?
Phase 2b measured its main depression score at Day 8, where GH001 beat placebo by 15.5 points. The Phase 3 plan shifts the primary measure to Week 4, and management has not shared the placebo-adjusted score difference from Phase 2b at that four-week mark.
Will one fixed dose work across diverse patient weights?
The Phase 1 bridging study showed 7 of 8 healthy volunteers reached a peak experience on the planned Phase 3 single dose. Management has not disclosed how much drug blood levels varied across those subjects or whether patient weight affects the response.
Has the company sold any shares under its ATM?
GH Research set up a $200 million at-the-market share sale program in May 2026 and had not used it as of August. Because the third-quarter release omits a cash flow statement and share count table, investors cannot see if any shares were issued.